A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

What this study is about

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

Who can join (things the study team will check)

✅ You may be able to join if…

• Provided electronic or written informed consent
• Men > 55, women > 65 years of age
• Type 2 diabetes mellitus requiring pharmacologic therapy, prediabetes (most recent HbA1c 5.7 to 6.4% and/or fasting glucose 100-125 mg/dL [5.6-6.9 mmol/L]) and/or metabolic syndrome. Metabolic syndrome is defined as > 3 of the following criteria (International Diabetes Federation 2006):
  • Body mass index ≥ 27 kg/m2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)
  • Fasting triglycerides ≥ 150 mg/dL (1.7 mmol/L) or treated hypertriglyceridemia
  • HDL-cholesterol (HDL-C) < 40 mg/dL (1.03 mmol/L) in men, <50 mg/dL (1.29 mmol/L) in women or treatment for this lipid abnormality
  • Systolic blood pressure (BP) ≥ 130 and/or diastolic BP≥ 85 mm Hg and/or treated hypertension
  • Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or HbA1c ≥ 5.7%
• Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group

🚫 You may not be able to join if…

• History of symptomatic CVD defined as prior MI, exertional or unstable angina, ischemic stroke, claudication, arterial revascularization for atherosclerosis or other CVD being actively managed by a cardiologist, e.g. atrial fibrillation, heart failure
• Planned arterial revascularization
• Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:
  • eGFR < 60 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org/professionals/kdoqi/gfr_calculator)
  • Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.
  • Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment
  • Weight > 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site
  • Inability to hold breath for > 10 seconds
  • Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., > 80 beats per minute at screening or prior to CCTA)
  • Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA
  • Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA
• Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy < 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)

Where this trial is running

• Chandler Clinical Trials, Chandler, Arizona, United States
• Scottsdale Clinical Trials, Scottsdale, Arizona, United States
• Sun City Research, Sun City, Arizona, United States
• Noble Clinical Research, Tucson, Arizona, United States
• Cardiovascular Research Foundation of Southern California, Beverly Hills, California, United States
• Amicis Research: Beverly Hills, Beverly Hills, California, United States
• Valiance Clinical Research - Canoga Park, Canoga Park, California, United States
• Cardiovascular Institute of San Diego, Chula Vista, California, United States
• Amicis Research: Granada Hills, Granada Hills, California, United States
• Valiance Clinical Research: Huntington Park, Huntington Park, California, United States
• HALO Diagnostics, Indian Wells, California, United States
• Scripps Health, La Jolla, California, United States

+ 112 more sites.

Who to contact

Ryann Sardinia · 7207398191 · ryann.sardinia@cleerlyhealth.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06112418.